Tetraphase Pharmaceu
(TTPH)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2016 | 03-2016 | 12-2015 | 09-2015 | 06-2015 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 178,311 | 189,863 | 205,912 | 222,459 | 242,079 |
| Receivables | 2,981 | 3,844 | 4,151 | 3,066 | 3,423 |
| TOTAL | $186,549 | $200,749 | $213,768 | $228,089 | $248,413 |
| Non-Current Assets | |||||
| PPE Net | 982 | 948 | 943 | 869 | 946 |
| Other Non-Current Assets | 199 | 199 | 206 | 237 | 251 |
| TOTAL | $1,181 | $1,147 | $1,149 | $1,106 | $1,197 |
| Total Assets | $187,730 | $201,896 | $214,917 | $229,195 | $249,610 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,542 | 1,490 | 2,857 | 1,735 | 5,786 |
| Accrued Expenses | 6,609 | 7,372 | 6,931 | 8,520 | 9,372 |
| TOTAL | $10,346 | $10,240 | $10,697 | $10,640 | $15,682 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 1,195 | 1,378 | 909 | 385 | 524 |
| Other Non-Current Liabilities | 137 | 151 | 165 | 180 | 0 |
| TOTAL | $137 | $151 | $165 | $180 | $N/A |
| Total Liabilities | $10,483 | $10,391 | $10,862 | $10,820 | $15,682 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,835 | 1,830 | 1,830 | 1,827 | 1,821 |
| Common Shares | 37 | 37 | 37 | 37 | 36 |
| Retained earnings | -303,561 | -286,393 | -269,652 | -251,536 | -233,493 |
| TOTAL | $177,247 | $191,505 | $204,055 | $218,375 | $233,928 |
| Total Liabilities And Equity | $187,730 | $201,896 | $214,917 | $229,195 | $249,610 |